MSC-Derived Small Extracellular Vesicles attenuate diabetic retinopathy through miR-29a-3p regulated microglia M1-like polarization
Quick Facts
- Publication title: MSC-Derived Small Extracellular Vesicles attenuate diabetic retinopathy through miR-29a-3p regulated microglia M1-like polarization
- Journal: Exp Eye Res
- Year: 2025
- DOI: 10.1016/j.exer.2025.110586
- PMID/PMCID: 40840646
Research overview
In this study, intravitreal injection of sEVs reduced retinal inflammation, mitigated vascular leakage, and suppressed M1-like microglia via the HMGB1/TLR4 signaling pathway. MSC-sEVs and miRNAs may be explored as promising therapeutic targets for DR.
Key findings
Diabetic retinopathy (DR), considered as a neurovascular disorder, significantly causes permanent vision loss and blindness worldwide among working-age adults.
The inflammation caused by M1-like microglia is involved in DR.
Mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) is an attractive candidate for inflammation modulation.
However, the regulatory effect of sEVs secreted by MSCs on M1 differentiation of microglia in diabetic retinopathy has not been thoroughly investigated.
Echo Biotech Role
Echo Biotech contributed miRNA profiling/sequencing and bioinformatic analysis.
Related platforms: Exoomics®
Related services and capabilities: EV miRNA Profiling / Sequencing
References
Original publication: MSC-Derived Small Extracellular Vesicles attenuate diabetic retinopathy through miR-29a-3p regulated microglia M1-like polarization Experimental eye research. 2025. DOI: 10.1016/j.exer.2025.110586. PMID/PMCID: 40840646.